{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:04:40Z","timestamp":1790867080933,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Tuberculosis (TB) remains a leading cause of mortality among people living with HIV\/AIDS, who face a tenfold higher risk of\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      (MTB) infection. TB-HIV coinfection complicates disease management due to drug interactions, overlapping toxicities, immune reconstitution inflammatory syndrome, and high treatment burdens, potentially driving drug resistance. The emergence of resistant MTB further exacerbates this challenge. This study evaluated the drug resistance profile of MTB in TB-confirmed samples from HIV-positive patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      An analytical cross-sectional study was conducted on 216 sputum samples from HIV patients on antiretroviral therapy at Jamot Hospital, Yaound\u00e9, Cameroon (June\u2013September 2022). Two consecutive samples per patient underwent fluorescent microscopy (Auramine-Rhodamine stain) and TB-Loop-Mediated Isothermal Amplification. DNA was extracted using the GenoLyse\n                      <jats:sup>\u00ae<\/jats:sup>\n                      kit (Hain Lifescience, Germany), and drug resistance profiles were assessed via GenoType\n                      <jats:sup>\u00ae<\/jats:sup>\n                      MTBDRplus and MTBDRsl line probe assays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>TB was confirmed in 12.04% (26\/216) of participants. Rifampicin (RIF) and isoniazid (INH) resistance were each detected in 50% (13\/26) of cases, with 23% (6\/26) exhibiting multidrug-resistance (MDR). Predominant mutations included rpoB MUT2B (15.38%) for RIF and inhA MUT2A (23.06%) for INH. Second-line resistance analysis revealed 61.54% (8\/13) resistance to kanamycin (KAN)\/amikacin (AMK)\/viomycin, 7.69% (1\/13) to AMK\/capreomycin\/viomycin, and 7.69% (1\/13) to KAN. Notably, 61.54% (8\/13) lacked the rrs wild-type probe, indicating resistance to injectable TB drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>High MDR-TB prevalence was observed among HIV-TB coinfected patients, underscoring the urgent need for enhanced resistance surveillance and optimized treatment strategies in TB\/HIV-endemic regions like Cameroon. Further research is warranted to elucidate HIV\u2019s role in driving TB drug resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_47_25","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:00:20Z","timestamp":1750431620000},"page":"182-190","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Characterization of Mycobacterium Tuberculosis in HIV Patients Receiving Antiretroviral Drugs in Cameroon"],"prefix":"10.4103","volume":"14","author":[{"given":"Gerades Dely","family":"Djoufack","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, Faculty of Natural Sciences, Redeemer\u2019s University, Ede, Osun State, Nigeria"},{"name":"Institute of Genomics and Global Health, Redeemer\u2019s University, Ede, Osun State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lem Edith","family":"Abongwa","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Faculty of Natural Sciences, Redeemer\u2019s University, Ede, Osun State, Nigeria"},{"name":"Institute of Genomics and Global Health, Redeemer\u2019s University, Ede, Osun State, Nigeria"},{"name":"Department of Microbiology and Parasitology, Faculty of Science, University of Bamenda, Bamenda, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan Olayemi","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Faculty of Natural Sciences, Redeemer\u2019s University, Ede, Osun State, Nigeria"},{"name":"Institute of Genomics and Global Health, Redeemer\u2019s University, Ede, Osun State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian Sydney Olufemi","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Faculty of Natural Sciences, Redeemer\u2019s University, Ede, Osun State, Nigeria"},{"name":"Institute of Genomics and Global Health, Redeemer\u2019s University, Ede, Osun State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir","family":"Gorden","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Faculty of Natural Sciences, Redeemer\u2019s University, Ede, Osun State, Nigeria"},{"name":"Institute of Genomics and Global Health, Redeemer\u2019s University, Ede, Osun State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M. Mendimi","family":"Nkodo","sequence":"additional","affiliation":[{"name":"Jamot Hospital Yaound\u00e9, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Happi","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Faculty of Natural Sciences, Redeemer\u2019s University, Ede, Osun State, Nigeria"},{"name":"Institute of Genomics and Global Health, Redeemer\u2019s University, Ede, Osun State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7283-2920","authenticated-orcid":false,"given":"Onikepe","family":"Folarin","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Faculty of Natural Sciences, Redeemer\u2019s University, Ede, Osun State, Nigeria"},{"name":"Institute of Genomics and Global Health, Redeemer\u2019s University, Ede, Osun State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12962-023-00479-z","article-title":"Tuberculosis prevention, diagnosis, and treatment financial profile during 2006-2021: PART A","volume":"21","author":"Meskini","year":"2023","journal-title":"Cost Eff Resour Alloc"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"281","DOI":"10.15585\/mmwr.mm6911a2","article-title":"Global epidemiology of tuberculosis and progress toward meeting global targets \u2013 Worldwide, 2018","volume":"69","author":"MacNeil","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4103\/ijmy.ijmy_143_23","article-title":"A critical review of risk factors influencing the prevalence of extensive drug-resistant tuberculosis in India","volume":"12","author":"Khan","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4103\/ijmy.ijmy_170_20","article-title":"Pattern of primary tuberculosis drug resistance and associated risk factors at Dubai health authority in Dubai","volume":"9","author":"Habous","year":"2020","journal-title":"Int J Mycobacteriol"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJMp2118145","article-title":"Covid-19\u2019s devastating effect on tuberculosis care \u2013 A path to recovery","volume":"386","author":"Pai","year":"2022","journal-title":"N Engl J Med"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coph.2018.05.013","article-title":"Drug-resistant tuberculosis: Challenges and opportunities for diagnosis and treatment","volume":"42","author":"Koch","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2213-2600(22)00092-3","article-title":"The intersecting pandemics of tuberculosis and COVID-19: Population-level and patient-level impact, clinical presentation, and corrective interventions","volume":"10","author":"Dheda","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijid.2020.03.001","article-title":"Commemorating world TB day 2020: \u201cIT\u2019S TIME\u2019 \u2013 It\u2019s time to end the global TB epidemic","volume":"92S","author":"Tiberi","year":"2020","journal-title":"Int J Infect Dis"},{"key":"R11-20260422","first-page":"3","article-title":"Profiles of isoniazid and rifampicin drug resistance conferring mutations in Mycobacterium tuberculosis among new and previously treated pulmonary tuberculosis cases from Kisumu County, Kenya","author":"Ogumbo","year":"2022","journal-title":"East Afr J Sci Technol Innov"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3389\/fmicb.2019.00794","article-title":"Molecular diagnosis of drug-resistant tuberculosis; a literature review","volume":"10","author":"Nguyen","year":"2019","journal-title":"Front Microbiol"},{"key":"R13-20260422","first-page":"7","article-title":"Predictors of drug-resistant tuberculosis among high-risk population diagnosed under national program conditions in the Littoral Region, Cameroon","volume":"42","author":"Mbuh","year":"2021","journal-title":"Biomed Res Int"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12879-022-07306-5","article-title":"Hot-spots of HIV infection in Cameroon: A spatial analysis based on demographic and health surveys data","volume":"22","author":"Sandie","year":"2022","journal-title":"BMC Infect Dis"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1186\/s12879-023-08575-4","article-title":"Prevalence and risk factors of tuberculosis among people living with HIV\/AIDS in China: A systematic review and meta-analysis","volume":"23","author":"Qi","year":"2023","journal-title":"BMC Infect Dis"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"e0262720","DOI":"10.1371\/journal.pone.0262720","article-title":"Prevalence and associated risk factors for tuberculosis among people living with HIV in Nepal","volume":"17","author":"Adhikari","year":"2022","journal-title":"PLoS One"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.11606\/s1518-8787.2020054002108","article-title":"TB-HIV co-infection: Spatial and temporal distribution in the largest Brazilian metropolis","volume":"54","author":"Cavalin","year":"2020","journal-title":"Rev Saude Publica"},{"key":"R18-20260422","first-page":"300","article-title":"Mycobacterium tuberculosis drug resistance in Ethiopia: An updated systematic review and meta-analysis","volume":"7","author":"Reta","year":"2022","journal-title":"Trop Med Infect Dis"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"17387","DOI":"10.1038\/s41598-021-96956-7","article-title":"Whole genome sequencing of clinical samples reveals extensively drug resistant tuberculosis (XDR TB) strains from the Beijing lineage in Nigeria, West Africa","volume":"11","author":"Olawoye","year":"2021","journal-title":"Sci Rep"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/ijmy.ijmy_88_23","article-title":"Safety of antituberculosis agents used for multidrug-resistant tuberculosis among patients attending the Jamot Hospital of Yaounde, Cameroon","volume":"12","author":"Mpoh","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/ijmy.ijmy_16_19","article-title":"Drug resistance profile of Mycobacterium tuberculosis isolates from patients referred to tuberculosis reference laboratory in Kosovo","volume":"8","author":"Bajrami","year":"2019","journal-title":"Int J Mycobacteriol"},{"key":"R23-20260422","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijtb.2016.11.031","article-title":"A study of clinical profile of cases of MDR-TB and evaluation of challenges faced in initiation of second line Anti tuberculosis treatment for MDR-TB cases admitted in drug resistance tuberculosis center","volume":"66","author":"Mukati","year":"2019","journal-title":"Indian J Tuberc"},{"key":"R24-20260422","first-page":"7","article-title":"High prevalence of rifampicin resistance associated with rural residence and very low bacillary load among TB\/HIV-coinfected patients at the national tuberculosis treatment center in Uganda","volume":"42","author":"Baluku","year":"2020","journal-title":"Biomed Res Int"},{"key":"R25-20260422","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijid.2021.03.093","article-title":"Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events","volume":"107","author":"Bachir","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R26-20260422","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S1473-3099(21)00808-2","article-title":"25 years of surveillance of drug-resistant tuberculosis: Achievements, challenges, and way forward","volume":"22","author":"Dean","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"R30-20260422","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijmy.ijmy_217_22","article-title":"Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review","volume":"12","author":"Putra","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R31-20260422","doi-asserted-by":"crossref","first-page":"356","DOI":"10.4103\/ijmy.ijmy_136_22","article-title":"Risk factors associated to multidrug-resistant tuberculosis in patients attending the deido district hospital of Douala \u2013 Cameroon","volume":"11","author":"Cecile","year":"2022","journal-title":"Int J Mycobacteriol"},{"key":"R32-20260422","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/2212-5531.307131","article-title":"New drugs and treatment recommendations \u2013 What are the consequences at the TB-laboratory?","volume":"9","author":"Hoffner","year":"2021","journal-title":"Int J Mycobacteriol"},{"key":"R33-20260422","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5588\/ijtld.20.0947","article-title":"Mortality due to TB-COVID-19 coinfection in India","volume":"25","author":"Kumar","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"R34-20260422","first-page":"e40442","article-title":"Characterization of genetic mutations in multi-drug-resistant isolates of Mycobacterium tuberculosis Bacilli conferring resistance to a second-line anti-tuberculosis drug","volume":"15","author":"Sharma","year":"2023","journal-title":"Cureus"},{"key":"R35-20260422","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4103\/ijmy.ijmy_120_23","article-title":"Genotype MTBDRsl version 2 and phenotypic drug resistance detection of Mycobacterium tuberculosis for fluoroquinolones and aminoglycosides","volume":"12","author":"Radhakrishnan","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R37-20260422","doi-asserted-by":"crossref","first-page":"e002280","DOI":"10.1136\/bmjgh-2019-002280","article-title":"Factors influencing diagnosis and treatment initiation for multidrug-resistant\/rifampicin-resistant tuberculosis in six sub-Saharan African countries: A mixed-methods systematic review","volume":"5","author":"Oga-Omenka","year":"2020","journal-title":"BMJ Glob Health"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_47_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:26:51Z","timestamp":1787837211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_47_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_47_25","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2025-04-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}